M. Alexander Otto
Medical Journalist at Medscape
Physician assistant, journalist. Over 20 years covering medicine. MIT journalism fellow, WebMD reporter. McClatchy, Bloomberg BNA, Washington Post background.
Articles
-
1 week ago |
medscape.com | M. Alexander Otto
Adding pembrolizumab to standard-of-care treatment improved event-free survival (EFS) in locally advanced head and neck squamous cell carcinoma (HNSCC), according to new results of the KEYNOTE-689 trial. “This new information supports changing the current standard of care to now include neoadjuvant and adjuvant pembrolizumab.
-
1 week ago |
portugues.medscape.com | M. Alexander Otto
A aprovação, em outubro de 2024, do inavolisibe para tratar o câncer de mama avançado destacou um problema crescente na oncologia mamária: o controle da hiperglicemia causada pelos inibidores da via fosfoinositídeo 3 quinase (PI3K) e da proteína quinase B (PKB). O inavolisibe faz parte de uma classe em franco crescimento de inibidores tendo como alvo a via da PI3K e da PKB para algumas pacientes com câncer de mama avançado ou com metástases.
-
2 weeks ago |
medscape.com | M. Alexander Otto
Circulating tumor DNA (ctDNA) saw more success in guiding adjuvant therapy decisions, in a study presented at the American Association for Cancer Research (AACR) Annual Meeting 2025. The phase 2 trial screened for ctDNA in 174 patients with early-stage mismatch repair–deficient solid tumors — 16 types in all, the majority colorectal cancer — within 10 weeks of R0 resections and standard-of-care adjuvant therapy. Twenty-two were ctDNA positive.
-
2 weeks ago |
medscape.com | M. Alexander Otto
The US Food and Drug Administration has approved a 100-mg liquid formulation vial of thiotepa (Tepylute), according to a press release from its maker, Shorla Oncology. Tepylute is an alkylating agent that does not require reconstitution like the freeze-dried powder form of thiotepa, which has been a standard-of-care oncology drug since the 1950s. Shorla’s new formulation is the only “ready-to-dilute multi-dose vial” of thiotepa for treating breast and ovarian cancer, the press release says.
-
2 weeks ago |
francais.medscape.com | M. Alexander Otto
La Mayo Clinic et Exact Sciences développent un test facile et non invasif pour détecter le cancer de l’endomètre chez les femmes présentant des saignements vaginaux anormaux. Placé dans le vagin, ce tampon particulier qui recueille le liquide vaginal identifie le cancer endométrial avec une très bonne spécificité. Les concepteurs espèrent épargner aux femmes la détresse et la douleur d'un prélèvement inutile de l'endomètre.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 161
- Tweets
- 271
- DMs Open
- Yes
important study for oncologists https://t.co/PdlN59TZlo
[tweet to keep acct active]
Fresh of the press. Indeed, it is a nasty little bug, but things are looking up on Long Island, anyways. Can you imagine 70 people all intubated at once? Like a sci-fi nightmare... @MDEdgeTweets @AmerMedicalAssn @Medscape @ivanoransky @hmkyale https://t.co/qKf5eZAwa8